Board of Directors
Sir Henry Riley
Sir Henry chairs our Board of Directors with a background of significant experience, especially in the technology sector.
He is a former Group Captain and test pilot with the Royal Air Force and his previous board positions include appointments as a Director of British Telecom, Managing Director of Phillips UK, a Director of Thales NL and Senior Director of BGT GmbH Aerospace.
He is also a Fellow of the Institute of Engineering and Technology.
Sir Henry is very aware of the real benefits of LEH Pharma’s innovative lens technology, as aside from his position on the board, he is also an Eyemax Mono patient himself, having undergone surgery in 2017.
Dr Bobby Qureshi
Chief Executive Officer / Founder
Bobby is a world-renowned eye surgeon, the most experienced laser cataract surgeon in the UK and arguably the most experienced AMD lens surgeon in the world.
He has been at the forefront of introducing innovative new lenses and surgery to the UK for the last decade and was the ﬁrst surgeon in the UK to perform many ground-breaking procedures including the Light Adjustable Lens procedure, the Synchrony accommodating lens implant, the Sensimed eye chip for glaucoma and Femtosecond Laser Cataract Surgery.
Bobby won the Greatest Innovation in Eye Surgery award in 2014, and was featured as a key future entrepreneur in the industry by the international peer reviewed journal The Ophthalmologist in 2016
Chief Financial Officer
Stijn spent more than 15 years with Loyens & Loeﬀ in Amsterdam, Tokyo and Dubai, before moving to EY in 2013 to lead its International Tax department in Dubai and manage the Private Clients practice for the MENA region. He has worked on international tax issues including global cross-border investments, group restructurings, and mergers and acquisitions. Stijn has advised clients in managing some of the most prominent real estate, hospitality and portfolio investments in Europe, US and Asia.
Dr Scott Robbie
Chief Scientific Officer
Scott is a consultant ophthalmic surgeon at Guy’s and St. Thomas’ NHS Foundation Trust in London specialising in corneal transplantation, cataract and lens implant surgery. He holds a PhD in Genetics from University College London.
Scott has collaborated with GlaxoSmithKline on novel therapeutics and worked on the ﬁrst gene therapy trial in the UKMBA from ESCP Europe. He holds a lectureship at the National Institute for Health Research Clinical Lectureship and his work has featured in over 30 peer-reviewed publications.
Chief Operating Officer
Mr Muhuseen holds a BSc (Hons) and a PG Dip in Information Technology and Computing from the University of Portsmouth. Zulfy has spent the last seven years within the London Eye Hospital Group and the last two years with LEH Pharma and the iolAMD project. He has been responsible for marketing, international operations and logistics, and assisting with regulatory matters for LEH Pharma.